In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application
Brlek, P., Bulić, L., Shah, N., Shah, P. & Primorac, D. (2025). In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application. International Journal of Molecular Sciences, 26. (6). doi: 10.3390/ijms26062568
Brlek, Petar, et al. "In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application." International Journal of Molecular Sciences, vol. 26, no. 6, 2025. https://doi.org/10.3390/ijms26062568
Brlek, Petar, Luka Bulić, Nidhi Shah, Parth Shah and Dragan Primorac. "In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application." International Journal of Molecular Sciences 26, no. 6 (2025). https://doi.org/10.3390/ijms26062568
Brlek, P., et al. (2025) 'In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application', International Journal of Molecular Sciences, 26(6). doi: 10.3390/ijms26062568
Brlek P, Bulić L, Shah N, Shah P, Primorac D. In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application. International Journal of Molecular Sciences [Internet]. 2025 March 13 [cited 2025 March 19];26(6). doi: 10.3390/ijms26062568
P. Brlek, L. Bulić, N. Shah, P. Shah and D. Primorac, "In Silico Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application", International Journal of Molecular Sciences, vol. 26, no. 6, March 2025. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:065299. [Accessed: 19 March 2025]